Healthy volunteers needed to test new version of cancer drug

NCT ID NCT07639905

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new formulation of the cancer drug HRS-2189 in 28 healthy adults aged 18-45. The goal is to compare how the body absorbs the new versus the old tablet version and to check for safety. Participants will take a single dose of each formulation in random order, with a break in between. This study does not aim to treat cancer, but to gather important information for future drug development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230601, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact